Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 01, 2015 8:31 PM ET

Pharmaceuticals

Company Overview of H3 Biomedicine Inc.

Company Overview

H3 Biomedicine Inc., a biopharmaceutical company, is engaged in the discovery and development of small-molecule drugs to treat cancer. H3 Biomedicine Inc. has a strategic collaboration with Selvita S.A. The company was founded in 2010 and is based in Cambridge, Massachusetts. H3 Biomedicine Inc. operates as a subsidiary of Eisai Inc.

300 Technology Square

Fifth Floor

Cambridge, MA 02139

United States

Founded in 2010

Phone:

617-252-5000

Key Executives for H3 Biomedicine Inc.

President and Chief Executive Officer
Scientific Founder
Age: 58
Scientific Founder
Senior Vice President of Planning and Operations
Senior Vice President of Clinical Development
Compensation as of Fiscal Year 2014.

H3 Biomedicine Inc. Key Developments

H3 Biomedicine Inc. Presents at Boston Biotech BD Boston Conference, Mar-26-2014 04:00 PM

H3 Biomedicine Inc. Presents at Boston Biotech BD Boston Conference, Mar-26-2014 04:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Markus Warmuth, President and Chief Executive Officer.

H3 Biomedicine Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 01:50 PM

H3 Biomedicine Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 01:50 PM. Venue: Apella, 450 East 29th Street, New York, NY 10016, United States. Speakers: Markus Warmuth, President and Chief Executive Officer.

H3 Biomedicine Inc and Selvita Announce Strategic Collaboration to Develop Precision Cancer Medicines

H3 Biomedicine Inc. and Selvita announced that they have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and druggability of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets. Together, the two companies have the know-how to leverage data from the new target opportunities revealed through cancer genomics.

Similar Private Companies By Industry

Company Name Region
Acetylon Pharmaceuticals, Inc. United States
Alteris Therapeutics Inc. United States
Balboa Biosciences Inc. United States
Chugai Pharma USA, LLC United States
Prevention Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H3 Biomedicine Inc., please visit www.h3biomedicine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.